View all veterinary jobs
Presented by Dr Sam Taylor BVetMed(Hons) CertSAM DipECVIMCA FRCVS, the series is aimed at the whole practice team, from new grads to experienced surgeons and nurses.
The sessions are:
Virbac says the series "provides a practical, flexible learning format that fits around busy clinical schedules, offering clear guidance on diagnosis, treatment and longterm management."
https://www.virbac-hub.co.uk
The series, titled "Under pressure: management of feline hypertension and concurrent disease", is available on the Ceva Academy website and consists of eight short videos offering 1.5 hours CPD.
It's presented by Rosanne Jepson BVSc MVetMed PhD DipACVIM DipECVIM PGCertVetEd FHEA MRCVS, professor of small animal internal medicine and nephrology at the Royal Veterinary College (pictured).
The series is designed to help delegates recognise feline hypertension, understand its relationship with conditions including chronic kidney disease and hyperthyroidism, and apply practical, evidence-led management strategies.
It also offers practical guidance on complex case management and an overview of diagnosis and treatment pathways for CKD and hyperthyroidism.
https://ceva.vbms-training.co.uk
For the study1, which was led by Professor David Gardner and Dr Rebecca Brociek and published in Frontiers in Veterinary Science, researchers analysed opportunistically collected kidney samples from 58 domestic cats, seven domestic dogs, 24 Scottish wildcats and three zoo wildcats.
Using chemical analyses, the team discovered that cats accumulate a rare group of modified triglycerides, some with unusual chemical bonds or branched structures, that are very rarely observed in other mammals.
Dogs did not show this pattern at all, and the feral Scottish Wildcats showed it only occasionally.
Dr Brociek said: "Why these types of unusual fats accumulate in domestic cat kidneys, even from an early age, may offer an important clue as to why domestic cats are particularly prone to chronic kidney disease, one of the most common and serious illnesses affecting older cats."
The researchers say that this distinctive lipid buildup inside kidney cells could be an early sign of long‑term stress within the kidney, potentially contributing to tissue damage over time.
Professor Gardner added: "We are hopeful that soon we will understand why these unusual fats accumulate in domestic cats - we just have to collect the evidence to find the proof.
"If true, we believe we could develop a supplement or modified diet to help prevent these unusual lipid structures from accumulating, ultimately benefitting the long-term health of our companion animals."
The discovery opens a new area of investigation into feline biology, suggesting that cats’ unique metabolism may predispose them to kidney problems. It could eventually lead to better diagnostic tools, improved diets, and new treatments for protecting cats' kidney health.
Reference
The study first set out to address whether the higher proportional mortality previously reported for Pugs with PLE in referral care is also seen in dogs managed only in primary care by looking at 51 cases from VetCompass data.
In the study, 43% of Pugs died presumed due to PLE, with over half of these deaths occurring within three months of diagnosis.
Most deaths were recorded as euthanasia (64%), with the remainder recorded as unassisted deaths.
The underlying cause for the PLE diagnosis in most Pugs in the study was not identified.
Clinical signs at diagnosis commonly included diarrhoea, vomiting, inappetence, lethargy, weight loss and increased drinking.
At the time of death, additional signs reported included pale mucous membranes, seizures and anaemia, which the authors noted have not been reported in the literature previously.
Treatments prescribed were variable and included dietary therapy, prednisolone, clopidogrel, chlorambucil, cyclosporin and/or cobalamin supplementation.
Pugs treated with prednisolone or clopidogrel were significantly more likely to be alive after three months, but this effect did not persist at one or two years after diagnosis.
Dr Aarti Kathrani, lead author of the study, said: “The results of our study will help to increase awareness and highlight the outcome and various causes of death in Pugs with protein-losing enteropathy.
"We hope the results will also help drive much-needed further research into the mechanism, pathophysiology and consequence of this disease, which is needed to help discover effective therapeutic targets that could help improve the prognosis of this guarded condition.”
The cross-sectional study, published in PLOS One, evaluated 898 dogs across 14 breeds and assessed conformational risk factors associated with BOAS.
Only 11% of Pekingese were graded free of BOAS.
Japanese Chins also showed high levels of disease, with only 17.4% graded unaffected.
King Charles Spaniels, Shih Tzus and Boston Terriers demonstrated intermediate risk profiles.
Cavalier King Charles Spaniels, Pomeranians, Boxers and Chihuahuas had substantially lower proportions of clinically affected dogs.
Across all breeds, increased facial shortening, dynamic nostril collapse and higher body condition score were significantly associated with BOAS severity.
Francesca Tomlinson, lead author and PhD researcher at the University of Cambridge, said: “Our research shows that BOAS varies widely between brachycephalic breeds.
"By understanding these differences and identifying key risk factors, we can move towards more targeted and effective strategies to improve welfare.”
The findings provide updated comparative data for clinicians advising owners on risk, weight management and early respiratory grading, and support structured respiratory grading schemes, including those led by The Royal Kennel Club.
References
The clinic sits within the Queen Mother Hospital for Animals’ Nephrology and Urology service and will monitor dogs during the three months after an AKI episode, when ongoing complications such as high blood pressure can emerge.
Access is via referral from the patient’s primary care veterinary practice.
Ahead of each appointment, owners complete a pre-appointment questionnaire about the dog’s wellbeing at home.
Patients then receive a clinical re-examination with the Nephrology and Urology team, with support from Emergency and Critical Care specialists.
Monitoring includes blood and urine testing and blood pressure measurement, with ultrasound considered depending on discussion at the appointment.
Owners attending the clinic can opt into a longitudinal research study looking at longer-term outcomes after AKI.
Professor Rosanne Jepson, Professor in Small Animal Nephrology and Internal Medicine at the RVC, said: “We hope that clients who are keen to attend this clinic will be willing to also participate in a study so that we can keep in touch with owners and dogs that have been treated for AKI, monitoring their clinical response and also quality of life, so that in the future we can better understand and continually give the very best care in this important recovery period.”
https://rvc.uk.com/renal-clinic
The session, From Early Care to Lifelong Health: Diarrhoea Management in Puppies and Kittens, will explore evidence suggesting early-life acute intestinal disorders can have lasting effects on gut integrity, immune function and the risk of chronic disease.
Purina says the discussion will focus on practical approaches that teams can apply in practice, including when antibiotic therapy is appropriate in young patients and how to minimise antibiotic-associated dysbiosis.
Topics include mechanisms by which enteritis — including giardiasis and parvoviral enteritis — may compromise gut integrity and increase chronic disease risk, along with best-practice protocols for managing acute diarrhoea to mitigate dysbiosis, preserve gut barrier function and potentially reduce future gastrointestinal and dermatological disorders.
The round table will be chaired by Jan S. Suchodolski MedVet, DrVetMed, PhD, AGAF, DACVM, with contributions from Ana Rostaher Prof, Dr med vet, Dipl ECVD, RCVS; Camille Torres-Henderson DVM, DABVP (Canine/Feline), DACVIM (Nutrition); Stefan Unterer Prof, Dr med vet, Dr habil, Dipl ECVIM-CA; and Michelle van Lienden DVM.
Natalia Wagemans, Head of the Purina Institute, said the aim is to provide “practical, evidence-based insights” that veterinary professionals can apply “immediately to improve long-term outcomes for pets”.
The event is free to attend, will be recorded and made available on demand for registered participants, and will offer live audio and subtitles in more than 50 languages.
https://events.purinainstitute.com/login/purinainstitute/MicrobiomeForumRoundTable2026
Marketed since 2016, Thyronorm is an award-winning liquid formulation that simplifies administration compared to tablets and enables precise dosing for both veterinary surgeons and pet owners.
During the product handover veterinary practices can continue to buy Thyronorm from their usual wholesaler, and all practice support activities and retrospective commercial rebates remain unchanged.
Virbac says it is working closely with Norbrook to make sure all practice support activities are smoothly handed over from Norbrook Account Managers to Virbac Territory Managers.
https://uk.virbac.com
The new guidelines are freely available in the Journal of Feline Medicine and Surgery (JFMS), along with new consensus guidelines for vets and a guide for caregivers.
Samantha Taylor, iCatCare Veterinary Specialist Consultant and co-author and panel chair for the guidelines said: “There have been significant developments in the treatment of feline diabetes mellitus since the publication of the 2015 ISFM diabetes guidelines.
"Experts in the disease from the USA, Netherlands, UK, Australia and Italy have collaborated on a much-needed update and the resulting 2025 iCatCare consensus guidelines are an essential information resource for vets diagnosing and treating diabetes mellitus in cats.”
https://internationalcatcare.cmail20.com/t/i-l-znwll-tykyklax-k/
Vikaly is indicated for the nutritional and medical management of chronic kidney disease in adult and senior cats with proteinuria, from IRIS stage 2.
The new diet delivers the same therapeutic dosage as benazepril tablets (0.5–1 mg/kg bodyweight/day).
Nutrition-wise, Vikaly is low phosphorus (0.5% as fed), has reduced protein (30% as fed), contains omega-3 fatty acids (1.2%, including 0.6% EPA & DHA) and offers high metabolisable energy (416 kcal/100g).
Virbac highlights data showing that CKD remains the leading cause of mortality in cats over five years old and affects up to 40% of feline patients over the age of ten1,2.
The company says administering daily treatment is recognised as a major issue for CKD cat owners with 45% of owners not administering treatment daily as they should and 51% of owners citing administration difficulties as the reason why3.
This new product eliminates the need to administer medication separately, which could completely transform treatment compliance, removing the risk of missed doses and reducing stress for both cats and their owners.
Virbac says that due to the pharmacokinetic profile of benazepril, which is incorporated into the kibble, at an equivalent dose Vikaly displays greater ACE inhibition than benazepril tablets4.
The rate of food consumption also does not affect plasma Benazeprilat levels, ensuring consistent treatment efficacy regardless of the cat’s feeding behaviour5.
Virbac says that in practice, this means that even if the cat being treated consumes less than 50% of their daily ration, efficacy is maintained with ACE activity similar to that of benazepril tablets.
Benazepril has a wide therapeutic margin, tolerated to 20x the minimum effective dose (10mg/kg) for 52 weeks, with the first signs of toxicity being reduced erythrocytes counts & ovary/oviduct weights6.
Virbac says that with Vikaly, these levels cannot be reached because the active ingredient is contained in food, which would require a cat to consume more than 10 times their daily ration.
Vikaly is presented in a 1.5kg bag, which equates to a 30 day supply for a 4.5kg cat with normal bodyweight.
It can be fed alongside wet food, providing that the cat consumes at least 50% of their daily ration before being given the wet food.
The daily ration can also be administered in several smaller meals throughout the day, to accommodate the individual preferences of the cat and to promote consistent food intake.
Vikaly is a prescription diet. Or 'POD', I guess.
Purina says it is common for dogs with gastrointestinal disturbances not to digest fat properly1, resulting in water secretion in the gut and loose stools2, production of anti-inflammatory compounds2 and altered microbiome composition 3,4.
The company says a limited fat diet can help, but some conditions, such as hyperlipidaemia, require even lower fat levels, such as found in the new EN Low Fat diet.
If you go to stand P20 and watch a short video about the new diet, you'll be entered into a draw to with prizes which include shopping vouchers, gym bags and umbrellas.
Vets from the Purina Technical Support Line will also be on the stand to answer questions about the new product.
The new resource contains webinars, vet-written articles and podcasts covering topics including the microbiome, the gut’s role in immunity and toxin ingestion.
The resources support NVS's range of dietary products: Prorestore +, Movipet, Duostart, Glandvet, Activated Charcoal, Duotox and Digestive Paste.
Malcolm Dickinson, Head of Product Management at NVS, said: “The new products are all designed with vets and their patients in mind.
"They’re useful everyday products to help combat some of the most commonly seen conditions in practice.
“We hope the hub will act as a central base of knowledge that veterinary teams can refer back to time and time again.
"The webinar and podcasts in particular are well worth a listen and a watch as they are full of useful information delivered by vets.”
https://www.nvsweb.co.uk/our-brands/select-from-nvs/digestive-health-hub
A graduate of the University of Córdoba, Spain, Sonya trained and worked across Europe and the United States, including at the Animal Health Trust, The Royal Veterinary College, Colorado State University and Nottingham University.
Her clinical interests span neurology, ophthalmology, muscular disorders, and infectious diseases, and she is widely recognised for her contributions to equine research.
She continues to contribute to ongoing studies in exercise biomarkers, toxicology, and infectious disease management, and regularly presents her findings at national and international veterinary conferences.
Andrew Jones, Clinical Director and Specialist Surgeon at CVS Endell Equine Hospital said: “Internal medicine specialists such as Dr. Gonzalez-Medina, with her comprehensive expertise spanning multiple body systems, will be instrumental in enhancing Endell’s existing services."
The new service will cover a broad spectrum of equine medical conditions, including:
Andrew added: “Our area has lacked this type of service for patients in the past, meaning horses can now access advanced internal medicine care without traveling great distances.”
The Equine Internal Medicine Service is now accepting referrals and direct cases.
https://www.endellequinehospital.co.uk.
This allows patients to try the drug at lower cost, before progressing to the 30ml bottle for ongoing treatment.
Samantha Taylor, RCVS Recognised Specialist in Feline Medicine said: “It’s great we now have the option to prescribe the smaller 12ML bottle for starting cats on Senvelgo, as it means we don’t have to worry about wasting a 30ml bottle if it becomes evident that the cat requires insulin in the first couple of weeks.”
https://senvelgo.co.uk
The researchers say that previous research suggests that approximately 10% of diabetic cats are euthanised at the time of diagnosis, making it a significant cat welfare issue.
However, this figure was largely based on questionnaire-based research from several global locations.
This new study followed the survival of 1,053 cats with confirmed diabetes mellitus under UK primary-care practices in 2019, providing the most up-to-date baseline data on early death among diabetic cats in the UK, as well as examining risk factors for the development of diabetes among UK pet cats.
The study found:
Based on these findings, the researchers encourage veterinarians to more actively discuss diabetes mellitus risk with cat owners, particularly those with Burmilla and Burmese breeds, in the hope that raising awareness of the disease might improve outcomes through earlier diagnosis, and by taking actions that might prevent diabetes mellitus development in the first instance, such as preventing cats becoming obese.
Dr Oliver Waite, Senior Lecturer in Small Animal Medicine at Murdoch University, and primary author of the paper, said: “We hope that this new, large scale epidemiological study, investigating the second most common endocrine disease in cats, will help to highlight current as well as future areas to improve cat welfare.
"This is an exciting time for the management of diabetic cats but more work is still needed!”
Dr Dan O’Neill, Associate Professor in Companion Animal Epidemiology at the RVC, and co-author of the paper, said: “This new VetCompass study shows the value of everyone working in primary care practice sharing their anonymised clinical data to get a better understanding of real-world animal health.
"Awareness of the scale of the diabetes mellitus issue revealed here can empower veterinary professionals to engage in more conversations with owners about diabetes mellitus prevention in predisposed cats.”
The range will include Vetoryl 20mg, 30mg and 60mg hydrolysed chicken flavoured tablets, which can be broken into halves or quarters.
The new Vetoryl tablets will come in packs of 30 tablets, although no word from Dechra as to when they'll arrive.
Thomas Johnson, Vetoryl brand manager at Dechra, said: “We are delighted that Vetoryl Flavoured Tablets for Dogs will soon be available, which will provide vets and pets owners with easy to administer, flavoured tablets to provide additional dosing flexibility.
"This, together with our commitment to providing extensive technical support and resources, will ensure that Vetoryl continues to be the UK’s leading licensed medical treatment for Cushing’s syndrome.”
The factsheets, which cover canine chronic bronchitis, feline asthma and equine asthma, are designed to help explain complex conditions more effectively, encourage earlier diagnosis, and improve treatment compliance.
The downloadable factsheets can be printed, emailed to clients, or displayed in waiting areas and on waiting room screens.
Jon Slattery MRCVS, Director of BreathEazy, said: “We often see a seasonal spike in respiratory cases at this time of year, particularly in animals with underlying conditions.
"Having owners on board and confident in managing their pet’s condition is a key part of treatment success.
"These factsheets offer a time-saving way for vets and nurses to educate clients, reinforce advice given in consults, and help owners understand how to support their pets at home.”
https://mailchi.mp/breatheazy/resourcedownload
www.breatheazy.co.uk
Virbac says this is the only wet product to provide separate species-specific dog and cat convalescence diets tailored to the unique nutritional needs of both species.
In an internal study conduct by Virbac, 86% of dogs with digestive issues improved within a week of using the diet1
The new diets are high in protein and low in carbohydrate and they can be used alone or in combination with the company's dry diets (suggested 50/50 split).
Andrew Connolly, Marketing Director – UK & Ireland at Virbac said: “We’re thrilled with the overwhelmingly positive feedback we've received on our new Veterinary HPM Digestive Support wet diets.
“Practices and pet owners alike are commenting on the extraordinary palatability of the diets and their effectiveness, particularly with convalescing and inappetent pets”.
The new presentation is honey-flavoured and is available in 30ml or 100ml bottles with a syringe for precise dosing.
It has a two-year shelf life and a broached shelf life of six months.
Dechra companion animal brand manager, Thomas Johnson, said: “The addition of Felimazole Oral to our product range will provide vets with the flexibility to prescribe Felimazole as either a tablet or oral solution to accommodate the preferences of both the cat and its owner.
"This, combined with our extensive endocrinology resources, will ensure that vets have all the necessary tools to support their feline hyperthyroid cases.”
https://www.dechra.co.uk/cushings-connect
https://www.dechra.co.uk/addisons-connect
https://www.dechra.co.uk/search?q=felimazole#/search=Felimazole
https://apps.apple.com/gb/app/dechra-endocrinology-app/id1660737534
The webinars are primarily aimed at veterinary surgeons, but there was a good turnout of nurses at the Cushing's session at the London Vet Show, so this series may also be of interest to RVNs.
The webinars will be presented by Professor Ian Ramsey, Ellen Behrend, Joezy Griffin, Professor Jill Maddison and Imogen Schofield.
They'll focus on the diagnosis, management and treatment of dogs with Cushing’s and will include information about Dechra’s predictor tool to help vets identify and progress suspected Cushingoid cases to a definitive diagnosis.
The webinars will also cover the importance of ongoing monitoring to optimise control of the syndrome and practical tips and tricks to help owners maximise compliance and optimise the quality of life of patients.
The full webinar schedule is as follows:
Trilotab is licensed for the treatment of pituitary-dependent hypercortisolism (PDH) caused by an adrenocorticotrophic hormone (ACTH)-secreting pituitary adenoma, which accounts for 85% of spontaneous cases of Cushing’s, and for the treatment of adreno-dependent hyperadrenocorticism (ADH) caused by a cortisol-secreting adrenocortical tumour (ACT), which accounts for the remaining 15% of spontaneous cases1.
The new tablet is divisible into halves and quarters to facilitate dose adjustment and make administration easier.
Divided tablets remain stable outside of the blister packaging until the next dose is due, thereby avoiding wastage.
Trilotab tablets are chewable and chicken-flavoured to help improve treatment compliance.
They contain hydrolysed chicken flavouring so they can be prescribed for pets allergic to chicken.
Trilotab is administered once daily with food with a starting dose of 2mg trilostane/kg bodyweight.
The new tabs are available in three presentations: 10mg, 30mg, and 60mg presentations, which Virbac says should help practices reduce their dispensary stockholding.
Andrew Connolly, Marketing Director – UK & Ireland at Virbac, said: ‘The complex nature of Cushing’s syndrome in dogs can make it a challenging condition to manage for both the clinician and the pet owner.
"With the requirement for lifelong treatment, it is our hope that Trilotab’s easy administration and simplified dosing protocols will genuinely help to improve the lives of dogs affected by the disease, whilst making the clinician and pet owner’s lives just a little bit easier too!"
This, say the authors, could lead to shorter hospitalisation time and less stress for donor cats.
For the study, researchers at the Royal Veterinary College measured the systolic blood pressure of 100 client-owned cats which had been randomly assigned to receive IVFT or no fluid after blood donation.
Owners were also contacted following donation to record any changes in their cat.
The results showed no significant difference in blood pressure between cats that received post-donation IVFT and those that didn't.
The main reported changes were minor bruising at the venepuncture site and mild lethargy, with no significant difference between the IVFT and no-IVFT groups.
These findings suggest that IVFT post-blood donation may not be necessary, as haemodynamic stability appears to be maintained despite the loss of blood.
Dr Guedra Allais, lead author of the study, said: "Our study showed no significant difference in blood pressure at different time points in feline donors that received intravenous fluid compared to others that didn’t receive any fluid.
"Other perfusion parameters such as capillary refill time, heart rate and pulse quality were not evaluated, and we recommend considering intravenous fluid in any feline donors if any major changes are detected on post donation physical examination.”
A team of researchers led by Tim Mair, CVS Equine Veterinary Director and Specialist in both Equine Internal Medicine and Equine Soft Tissue Surgery at Bell Equine Veterinary Clinic, will review 100 cases of colitis in adult horses and 100 controls referred to seven equine veterinary hospitals in the UK: five CVS equine veterinary hospitals as well as Rossdales Equine Hospital and University of Liverpool’s equine hospital.
A set of diagnostic tests on blood and faeces will be performed in these cases.
The laboratory tests will include: small redworm serology, culture and PCR of faeces for Salmonella spp, PCR of faeces for Clostridioides difficile and Clostridium perfringens, ELISA of faeces for toxins of C.difficile and C.perfringens, PCR of faeces for coronavirus.
The clinical features, laboratory results, treatments and outcomes will also be recorded.
Tim said: “Acute colitis accounts for around 5% of admissions to referral hospitals.
"And of those who are referred with it, half will not survive but there is very limited evidence available.
"So it’s vital that we build our evidence-base of this life-threatening condition.
"We hope that the outcomes of our new study will lead to a greater understanding of the causes and better inform veterinary treatment of colitis in UK adult horses.”
The Colitis in Adult Horses study is supported by a research grant from CVS, and funding for the small redworm ELISA will be given from Austin Davis Biologics.
The study started at the beginning of 2024 and the first horses have been recruited.
The results of the study are expected to be published in 2025.
Across Europe, the company has over 30 technical experts who get over 2,500 technical calls each year about Cushing’s.
The company also publishes the Dechra Academy, which provides a range of free online courses for vet nurses.
There's also Dechra’s endocrinology app which was developed using data from the Royal Veterinary College’s VetCompass database to help vets diagnose and manage the endocrine disorders Addison’s disease (hypoadrenocorticism) and Cushing’s syndrome.
For owners, Dechra publishes the 'Suspecting Cushing’s' website and has created the Cushing’s monitoring app to help simplify the management process, improve compliance with medication and increase engagement in the dog’s care.
Sarah Musgrave, companion animal brand manager at Dechra, said: “Dechra has extensive experience in endocrinology.
"Cushing’s can be a challenge to identify, diagnose and manage and our ‘They’ve got Cushing’s. You’ve got us’ initiative demonstrates the comprehensive support that we have available for both vets and dog owners to help ensure that dogs with Cushing’s live long and healthy lives.”
The Diabetic Clinical Score is a quick, standardised scoring system to record the clinical signs of diabetes in a patient, which was designed by Royal Veterinary College Internal Medicine Specialist Dr. Stijn Niessen.
The scoring system has been turned into a pet diabetes app which allows clients to record and monitor the impact of treatment.
CVS' aim is to use the recently validated tool in over 80% of patient cases to improve the treatment and control of diabetes whilst supporting the practice team to develop their skills in managing the condition.
Participating practices will use the DCS, alongside blood glucose measurements, to diagnose and monitor patients.
Veterinary nurses will refer animals coming in for six-monthly Healthy Pet Club check-ups to a vet for a possible diabetes diagnosis, whilst vets diagnosing diabetes will introduce owners and patients to the DCS to record a diabetes log, to help manage the condition.
To upskill and develop colleagues in the use of the DCS, dedicated vet and nurse training sessions have been held by the clinical leadership team, including a kick-off ‘diabetes day’ which focussed on current thinking and introduced the DCS tool.
CVS teams have also grouped together to agree a coordinated approach to managing pets with diabetes in their practice.
Supporting diabetes resources have also been drafted for practices, including new clinical guidelines, supporting paperwork and CPD.
Lara Wilson, Regional Clinical Lead at CVS said: “Diabetes is notoriously difficult to diagnose and different vets can use different approaches to managing cases.
“The Diabetic Clinical Score will help the whole team around the patient – the owner, vet and veterinary nurse – to effectively and cohesively manage their care.
It will implement joined-up thinking and help to put a standardised disease management framework in place.
“It will be fantastic to see the benefits that the Diabetic Clinical Score will bring to our patients and practices.
"I am certain that this will help contribute towards them providing some of the best diabetes clinical diagnosis and care in our profession.”